---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Phase of product development"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Phase of product development. Topics: Regulatory status: Under review; rolling BLA initiated November 2025, completion anticipated by March 2027; BLA completion expected in the fourth quarter of 2026 for CIS-containing disease, May 2026, superseded in November 2026; BLA completion expected in 2026, November 2025, superseded in May 2026; Investigational status; 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Under review; rolling BLA initiated November 2025, completion anticipated by March 2027

> “Based on FDA feedback, initial BLA submission in BCG-unresponsive NMIBC to be broadened to include both CIS and high-grade papillary-only disease; completion anticipated in March 2027”
> “To incorporate the additional data, we now expect to complete the submission before the end of March 2027.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

> “Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)”

Source: [CG Oncology third-quarter 2025 results press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2025-financial-results-and)

> “This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we initiated in the fourth quarter of 2025”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

> “CG社は、2025年11月に米国で本剤のローリング申請を開始しました。”

Source: [Kissei Pharmaceutical Lancet Oncology publication press release (2026)](https://www.kissei.co.jp/news/uploaded/ac0d28038b8ced3e28ffd15df1f1d731.pdf)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### BLA completion expected in the fourth quarter of 2026 for CIS-containing disease, May 2026, superseded in November 2026

> “Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026”
> “We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and we are on track to finalize our submission in the fourth quarter 2026.”

Source: [CG Oncology first-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-first-quarter-2026-financial-results-and)

> “This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we expect to complete in the fourth quarter of 2026.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

> “BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026”
> “Completion of BLA submission in initial indication of BCG-unresponsive NMIBC with CIS with or without papillary disease Q4 2026”

Source: [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-4"></a>

### BLA completion expected in 2026, November 2025, superseded in May 2026

> “The Company initiated its rolling BLA submission for cretostimogene with complete submission expected in 2026.”

Source: [CG Oncology third-quarter 2025 results press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2025-financial-results-and)

> “This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we initiated in the fourth quarter of 2025 and expect to complete in 2026.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.1-5"></a>

### Investigational status

> “Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

> “We do not have any products approved for sale and have not generated any revenue from product sales.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-2.1.1-6"></a>

### Development phase: phase 3 trial supporting the BLA

> “We are evaluating the safety and efficacy of cretostimogene monotherapy in BOND-003 Cohort C, our ongoing Phase 3 clinical trial in Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary disease.”
> “Additionally, in April 2024, we initiated BOND-003 Cohort P, an exploratory study evaluating cretostimogene monotherapy in BCG-unresponsive papillary only NMIBC.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

> “BOND-003 Cohort P (BCG-unresponsive papillary only NMIBC) 12-month data December 2026”

Source: [CG Oncology third-quarter 2026 results press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-7"></a>

### FDA Fast Track and Breakthrough Therapy designations

> “today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.”

Source: [CG Oncology Fast Track and Breakthrough Therapy press release (2023)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-receives-both-fda-fast-track-and-breakthrough)

> “Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA for the treatment of BCG-unresponsive NMIBC with CIS with or without papillary disease.”

Source: [CG Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm)

<a id="topic-2.1.1-8"></a>

### Breakthrough Therapy designation for the combination with pembrolizumab

> “We have obtained Breakthrough Therapy designation from the FDA for cretostimogene for the treatment of BCG-unresponsive, high-risk NMIBC with carcinoma in-situ with or without Ta or T1 tumors to improve CR and for cretostimogene in combination with pembrolizumab for the treatment of NMIBC unresponsive to BCG”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-2.1.1-9"></a>

### Manufacturing readiness for the BLA

> “All BLA-enabling manufacturing activities supporting both regulatory filings have been completed.”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.1.1-10"></a>

### Second BLA planned for intermediate-risk and high-grade Ta disease

> “PIVOT-006 data will support a second BLA submission in intermediate-risk and high-grade Ta NMIBC anticipated in Q2 2027”

Source: [CG Oncology PIVOT-006 topline press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates)

<a id="topic-2.1.1-11"></a>

### Japan: filing planned after the U.S. submission is complete

> “当社は、米国での申請完了後、”
> “必要な資料を整え、国内で申請する予定です。”

Source: [Kissei Pharmaceutical Lancet Oncology publication press release (2026)](https://www.kissei.co.jp/news/uploaded/ac0d28038b8ced3e28ffd15df1f1d731.pdf)

<a id="topic-2.1.1-12"></a>

### China: phase 2 study sponsored by the licensee

> “A Single-arm, Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Cretostimogene Grenadenorepvec in Patients With BCG-unresponsive High-risk Non-Muscle Invasive Bladder Cancer”

Source: [ClinicalTrials.gov NCT07283835](https://clinicaltrials.gov/study/NCT07283835)

Additional sources: [MHLW orphan regenerative medical product designation (2025)](https://www.pref.nara.jp/secure/307355/06314.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
